Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 76

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 6
Chunk 76
---
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
(Start of the Remuneration Report for Australian Disclosure Requirements)

A.   Directors and Senior Management
------------------------------------

Our directors are as follows:

         Name                Age                Position             
---------------------------------------------------------------------
Geoffrey P. Kempler           70   Chairman of the Board of Directors
David A. Stamler              64   Chief Executive Officer           
Lawrence B. Gozlan            46   Director                          
Peter A. Marks(1) (2)         69   Director                          
Brian D. Meltzer(1)(2)        71   Director                          

Outsourced Company Secretary and Chief Financial Officer were as follows during the period:

         Name                Age                      Position                  
--------------------------------------------------------------------------------
Phillip Hains (3)             65   Company Secretary and Chief Financial Officer
Abby Macnish Niven (4)        43   Company Secretary and Chief Financial Officer

(1)   Member of the Audit Committee
-----------------------------------

(2)   Member of the Remuneration Committee and Share Plan Committee
-------------------------------------------------------------------

(3)        Phillip Hains resigned as CFO on 30 September 2024 and as Company Secretary on 17 November 2024     
---------------------------------------------------------------------------------------------------------------
(4)   Abby Macnish Niven was appointed as CFO on 30 September 2024 and as Company Secretary on 18 November 2024
Mr. Geoffrey Kempler has served as Chairman of our Board of Directors since November 1997; between November 1997 and August 2004 he served as our Chief Executive Officer and again assumed the position of Chief Executive Officer from June 2005 until January 2021. Mr. Kempler is one of the founders of our company. Mr. Kempler qualified as a psychologist with extensive experience in investment and business development. He served as a Chairman and Non-Executive Director of Opthea Limited (NASDAQ:OPT), from November 2015 until October 2020, is immediate past Chairman of Ausbiotech, Australia’s biotechnology organization, and is a member of the Industry Advisory Board at the Turner Institute of Brain and Mental Health at Monash University, and Chair of Hexima Ltd. Mr. Kempler holds a B.Sc degree in science from Monash University, Grad. Dip. App. Soc. Psych. degree from Swinburne University.
Dr. David Stamler, M.D. was appointed Chief Executive Officer in January 2021 and previously served as our